LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals

LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals 
Optina Is Currently in a Pivotal Phase IIb Trial -- First Oral Drug
for Diabetic Macular Edema; Phase II Run-In Trial for Ampion to Treat
Osteoarthritis of the Knee to Begin in 2013; Available for Download
at www.lifesciadvisors.com/clients/ampio/ 
NEW YORK, NY -- (Marketwire) -- 03/07/13 --  LifeSci Advisors, LLC, a
leading provider of investment research and investor relations
services in the life sciences sector, today announced that it has
initiated coverage of Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a
biopharmaceutical company focused on the rapid development of
therapies to treat prevalent inflammatory conditions for which there
are limited treatment options. Ampio's leading development candidates
are Ampion for osteoarthritis of the knee and Optina, which has the
potential to be the first oral therapy for diabetic macular edema. 
"Ampio's focus on developing therapies for inflammatory conditions
with limited treatment options and large market opportunities has the
potential to yield multiple marketed products," said Andrew I.
McDonald, Ph.D., Founding Partner at LifeSci Advisors. "For example,
Ampion for osteoarthritis of the knee address a market worth more
than $1.3 billion in the US annually, and the global macular edema
market addressed by Optina is rapidly approaching $2 billion per
year." 
Ampion is a patented, naturally occurring compound in the human body
that is derived from serum albumin, which has been safely used as a
therapeutic for decades. Ampio is initially developing this drug
candidate as an intra-articular injection to treat osteoarthritis of
the knee. Ampio announced that the FDA requested one Phase II
dose-escalation study as a run-in to the pivotal Phase III study. To
this end, the Company intends to conduct a Phase II dose-finding
study in patients with osteoarthritis of the knee that will be
followed shortly thereafter by a single, pivotal Phase III trial,
which could read out in 18 months. However, the compound may also
have activity in other inflammatory conditions. For example, Ampion
has the potential to be aerosolized as a treatment for allergic
rhinitis, or a synthetic form may eventually be used as a treatment
for autoimmune disorders.  
Optina (danazol) is an ultra-low dose version of an existing drug
that is being developed for diabetic macular edema. Ampio discovered
that an ultra-low dose acts differently than currently-used
therapeutic doses, allowing for strong patent protection. The fact
that the drug has an established clinical track record minimizes
safety risk and creates the possibility that Optina could be approved
on data from a single trial. On February 27, 2013, Ampio announced
that the first patient has been dosed in the Optina pivotal trial.
The Company has not announced a timeline for completing the trial;
however, an interim analysis is planned after 4 weeks. 
In a 47-page Initiation Report by LifeSci Advisors, we explain
Ampio's overall development strategy, including a device platform
that has been carved-out into a separate company and a pre-clinical
candidate that possesses a novel mechanism of action for cancer
treatment in addition to Ampion and Optina. The report provides a
deep look into the scientific rationale behind each of Ampio's
development programs, competing products and development programs,
and examines the patient population and market opportunity for each
drug candidate. 
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, www.lifesciadvisors.com. In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
Cytokinetics. 
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
website, www.lifesciadvisors.com.  
Important Disclosures:
 The research report described in this press
release is not intended as an offering, recommendation, or a
solicitation of an offer to buy or sell securities. The securities
discussed in LSA research reports may be unsuitable for some
investors depending on their specific investment objectives,
financial status, risk profile, or particular needs. Investors should
consider LSA reports as only a single factor in making their
investment decisions and should not rely solely on these reports in
evaluating whether or not to buy or sell the securities of the
subject company. LifeSci Advisors has been compensated by the company
that is the subject of the report described and future research
reports, investor relations services, and general consulting
services. Please read each report's full disclosures and analyst
background on the LSA website, www.lifesciadvisors.com, before
investing. LifeSci Advisors is not a registered investment adviser or
broker-dealer.  
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements.  
Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com  
Ampio Contact:
Rick Giles
Director of Investor Relations
Phone: (720) 437-6530
Email: rgiles@ampiopharma.com